S-32212 HCl | CAS# 847871-78-7 | 5-HT Inverse Agonist

MedKoo Cat#: 574046 | Name: S-32212 HCl

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

S-32212 HCl is an inverse agonist of the serotonin (5-HT) receptor subtypes 5-HT2CINI and 5-HT2CVSV. It is also an antagonist of the 5-HT2A receptor and the α2B-adrenergic receptor. S-32212 HCl decreases head twitching, penile erections, and drug discrimination induced by 5-HT receptor agonists in mice and rats. It reduces immobility time in the forced swim test and decreases marble burying in mice and rats indicating anti-depressant-like and anxiolytic activities.

Chemical Structure

S-32212 HCl

CAS#847871-78-7

Theoretical Analysis

MedKoo Cat#: 574046

Name: S-32212 HCl

CAS#: 847871-78-7

Chemical Formula: C25H29ClN4O2

Exact Mass:

Molecular Weight: 452.98

Elemental Analysis: C, 66.29; H, 6.45; Cl, 7.83; N, 12.37; O, 7.06

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 550.00
50mg	USD 1,350.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

S-32212 HCl, S32212 HCl, S 32212 HCl

IUPAC/Chemical Name

1,2-dihydro-N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-3H-benz[e]indole-3-carboxamide, monohydrochloride

InChi Key

RAKGNVNONBJBSW-UHFFFAOYSA-N

InChi Code

InChI=1S/C25H28N4O2.ClH/c1-27-13-15-28(16-14-27)23-17-19(8-10-24(23)31-2)26-25(30)29-12-11-21-20-6-4-3-5-18(20)7-9-22(21)29;/h3-10,17H,11-16H2,1-2H3,(H,26,30);1H

SMILES Code

CN1CCN(C2=C(OC)C=CC(NC(N3C(C=CC4=CC=CC=C45)=C5CC3)=O)=C2)CC1.Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO and water

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

S-32212 exhibits notable receptor interactions with Ki values of 6.6 nM and 8.9 nM for the serotonin (5-HT) receptor subtypes 5-HT2CINI and 5-HT2CVSV, respectively. It is a 5-HT2A receptor and the α2B-adrenergic receptor agonist, both with a Ki value of 5.8 nM. S-32212 demonstrates over 70-fold selectivity for these receptors among a panel of 80 receptors, enzymes, and ion channels. Its functional effects involve reducing GTPγS binding to Gαq and inhibiting phospholipase C (PLC) activity, showing EC50 values of 38 nM and 18.6 nM for cells expressing 5-HT2CINI and 5-HT2CVSV receptors, respectively.

In vitro activity:

The activity of S-32212 in this study involves its interaction with the turkey β1 adrenergic receptor in complex with transducing partners in the presence of the full agonist isoprenaline. The study focuses on understanding the conformational states of the receptor and the impact of ligands, including S-32212, on these states. Reference: J Am Soc Mass Spectrom. 2019 Mar;30(3):529-537. https://pubmed.ncbi.nlm.nih.gov/30511235/

In vivo activity:

S-32212, a potential antidepressant, targets human 5-HT(2C) receptors, acting as an inverse agonist to reduce Gα(q) activation and downstream signaling. It enhances receptor membrane expression, blunts the effects of 5-HT(2C) agonists on neurons, and hinders 5-HT-induced signaling at h5-HT(2A) receptors. S-32212 also strongly interacts with human α(2)-adrenoceptors (α(2A), α(2B), α(2C)), inhibiting noradrenaline-induced pathways. Reference: J Pharmacol Exp Ther. 2012 Mar;340(3):750-64. https://pubmed.ncbi.nlm.nih.gov/22178752/

	Solvent	mg/mL	mM
Solubility
	DMSO	25.0	55.19
	Water	25.0	55.19

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 452.98 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Gavriilidou AFM, Hunziker H, Mayer D, Vuckovic Z, Veprintsev DB, Zenobi R. Insights into the Basal Activity and Activation Mechanism of the β1 Adrenergic Receptor Using Native Mass Spectrometry. J Am Soc Mass Spectrom. 2019 Mar;30(3):529-537. doi: 10.1007/s13361-018-2110-z. Epub 2018 Dec 3. PMID: 30511235. 2. Dekeyne A, Brocco M, Loiseau F, Gobert A, Rivet JM, Di Cara B, Cremers TI, Flik G, Fone KC, Watson DJ, Papp M, Sharp T, Serres F, Cespuglio R, Olivier B, Chan JS, Lavielle G, Millan MJ. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: II. A behavioral, neurochemical, and electrophysiological characterization. J Pharmacol Exp Ther. 2012 Mar;340(3):765-80. doi: 10.1124/jpet.111.187534. Epub 2011 Dec 16. PMID: 22178753. 3. Millan MJ, Mannoury la Cour C, Chanrion B, Dupuis DS, Di Cara B, Audinot V, Cussac D, Newman-Tancredi A, Kamal M, Boutin JA, Jockers R, Marin P, Bockaert J, Muller O, Dekeyne A, Lavielle G. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization. J Pharmacol Exp Ther. 2012 Mar;340(3):750-64. doi: 10.1124/jpet.111.187468. Epub 2011 Dec 16. PMID: 22178752.

In vitro protocol:

In vivo protocol:

1. Dekeyne A, Brocco M, Loiseau F, Gobert A, Rivet JM, Di Cara B, Cremers TI, Flik G, Fone KC, Watson DJ, Papp M, Sharp T, Serres F, Cespuglio R, Olivier B, Chan JS, Lavielle G, Millan MJ. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: II. A behavioral, neurochemical, and electrophysiological characterization. J Pharmacol Exp Ther. 2012 Mar;340(3):765-80. doi: 10.1124/jpet.111.187534. Epub 2011 Dec 16. PMID: 22178753. 2. Millan MJ, Mannoury la Cour C, Chanrion B, Dupuis DS, Di Cara B, Audinot V, Cussac D, Newman-Tancredi A, Kamal M, Boutin JA, Jockers R, Marin P, Bockaert J, Muller O, Dekeyne A, Lavielle G. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization. J Pharmacol Exp Ther. 2012 Mar;340(3):750-64. doi: 10.1124/jpet.111.187468. Epub 2011 Dec 16. PMID: 22178752.

1. Millan, M.J., Mannoury la Cour, C., Chanrion, B., et al. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization. J. Pharmacol. Exp. Ther. 340(3), 750-764 (2012). 2. Dekeyne, A., Brocco, M., Loiseau, F., et al. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: II. A behavioral, neurochemical, and electrophysiological characterization. J. Pharmacol. Exp. Ther. 340(3), 765-780 (2012).